AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37422772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 37422841 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) markers
Number of subjects: 3289
Study 37422841 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear HRV measures
Number of subjects: 3289
Study 37422841 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable linear regression analyses
Number of subjects: 3289
Study 37422841 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 3289
Study 37423228 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg IV every 3 weeks)
Number of subjects: 453
Study 37423228 — intervention group
Group type: COMPARATOR
Intervention: Single-agent chemotherapy (vinorelbine or gemcitabine, dosing per local label)
Number of subjects: 453
Study 37423231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg once daily)
Number of subjects: 220
Study 37423231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 37423231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 220
Study 37423623 — intervention group
Group type: EXPERIMENTAL
Intervention: CAB+RPV long-acting (LA) administration
Number of subjects: 0
Study 37423647 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 812
Study 37423647 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab
Number of subjects: 812
Study 37423647 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 812
Study 37423647 — intervention group
Group type: COMPARATOR
Intervention: Active conventional therapy
Number of subjects: 812
Study 37423676 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation audio recording for three days after surgery
Number of subjects: 61
Study 37423676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 37423717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg monthly for 3 months
Number of subjects: 66
Study 37423717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 37423717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg monthly for 6 months (mepo/mepo)
Number of subjects: 66
Study 37423717 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by Mepolizumab 100 mg monthly for 3 months (pbo/mepo)
Number of subjects: 66
Study 37423801 — intervention group
Group type: EXPERIMENTAL
Intervention: H-SC (600 mg fixed-dose)
Number of subjects: 113
Study 37423801 — intervention group
Group type: COMPARATOR
Intervention: H-SC
Number of subjects: 113
Study 37423834 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg i.v. dissolved in 0.9% saline 150 ml
Number of subjects: 1154
Study 37423834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline 150 ml)
Number of subjects: 1154
Study 37423882 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-1β
Number of subjects: 0
Study 37423882 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-6
Number of subjects: 0
Study 37423882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor (TNF)
Number of subjects: 0
Study 37423902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 22
Study 37423933 — intervention group
Group type: EXPERIMENTAL
Intervention: NephroCheck bedside system
Number of subjects: 45
Study 37424023 — intervention group
Group type: EXPERIMENTAL
Intervention: Duhuo Jisheng Decoction (DHJSD) plus Tui-na manipulation
Number of subjects: 70
Study 37424023 — intervention group
Group type: COMPARATOR
Intervention: Tui-na manipulation alone
Number of subjects: 70
Study 37424311 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume group (20% TPI, 200 g RPM per week)
Number of subjects: 102
Study 37424311 — intervention group
Group type: COMPARATOR
Intervention: Meat group (25% TPI, 760 g RPM per week)
Number of subjects: 102
Study 37424386 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 139
Study 37424386 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 139
Study 37424700 — intervention group
Group type: EXPERIMENTAL
Intervention: DLBS3233 (100 mg once per day)
Number of subjects: 60
Study 37424700 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin XR (750 mg twice per day)
Number of subjects: 60
Study 37424700 — intervention group
Group type: EXPERIMENTAL
Intervention: DLBS3233 (100 mg once per day) + Metformin XR (750 mg twice per day)
Number of subjects: 60
Study 37424700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 37424866 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased myocardial triglyceride content (MTGC)
Number of subjects: 338
Study 37425161 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care mobile application combined with usual oncology care
Number of subjects: 120
Study 37425161 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 120
Study 37425294 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function (BRIEF) self-rating
Number of subjects: 144
Study 37425294 — intervention group
Group type: COMPARATOR
Intervention: Behavior Rating Inventory of Executive Function (BRIEF) parent-rating
Number of subjects: 144
Study 37425294 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity and Emotion Dysregulation Scale (IED-27)
Number of subjects: 144
Study 37425294 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall assessment of executive functioning
Number of subjects: 144
Study 37425294 — intervention group
Group type: EXPERIMENTAL
Intervention: Training of executive functioning
Number of subjects: 144
Study 37425298 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV load and QF-Ag
Number of subjects: 64
Study 37425298 — intervention group
Group type: EXPERIMENTAL
Intervention: TTV load and QF-Mg
Number of subjects: 64
Study 37425372 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid epicardial-endocardial ablation (HA)
Number of subjects: 154
Study 37425372 — intervention group
Group type: COMPARATOR
Intervention: Endocardial ablation (CA)
Number of subjects: 154
Study 37425493 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic arrays
Number of subjects: 755
Study 37425721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronically implanted brain-computer interface (BCI)
Number of subjects: 1
Study 37425726 — intervention group
Group type: EXPERIMENTAL
Intervention: MtrCDE efflux pump
Number of subjects: 0
Study 37426086 — intervention group
Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment
Number of subjects: 238
Study 37426102 — intervention group
Group type: EXPERIMENTAL
Intervention: Family psychoeducation intervention (six sessions over 1.5 months)
Number of subjects: 25
Study 37426102 — intervention group
Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 25
Study 37426178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasafytol
Number of subjects: 25
Study 37426178 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study 37426179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention diet (rich in whole grain, fruit and vegetables, margarine/oil and seafood)
Number of subjects: 50
Study 37426179 — intervention group
Group type: COMPARATOR
Intervention: Control diet (rich in meat and high-fat dairy)
Number of subjects: 50
Study 37426179 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention diet
Number of subjects: 50
Study 37426179 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study 37426430 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSC) infusion at 6 and 7 weeks post-transplantation
Number of subjects: 34
Study 37426430 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MSC infusion)
Number of subjects: 34
Study 37426947 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-Delta
Number of subjects: 4113
Study 37426947 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta
Number of subjects: 4113
Study 37426947 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron
Number of subjects: 4113
Study 37426952 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-positive participants
Number of subjects: 5963
Study 37426952 — intervention group
Group type: COMPARATOR
Intervention: COVID-negative participants
Number of subjects: 5963
Study 37426952 — intervention group
Group type: EXPERIMENTAL
Intervention: General and fatigue-related symptoms
Number of subjects: 5963
Study 37426952 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom classes at 3 months
Number of subjects: 5963
Study 37427145 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-21 with radiotherapy
Number of subjects: 131
Study 37427145 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 with radiotherapy
Number of subjects: 131
Study 37427145 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-21 without radiotherapy (observation)
Number of subjects: 131
Study 37427145 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP-14 without radiotherapy (observation)
Number of subjects: 131
Study 37427146 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-21 with radiotherapy
Number of subjects: 695
Study 37427146 — intervention group
Group type: EXPERIMENTAL
Intervention: R-CHOP-14 with radiotherapy
Number of subjects: 695
Study 37427146 — intervention group
Group type: COMPARATOR
Intervention: Observation after R-CHOP-21
Number of subjects: 695
Study 37427146 — intervention group
Group type: COMPARATOR
Intervention: Observation after R-CHOP-14
Number of subjects: 695
Study 37427254 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal aptitudes related to behaviors (self-efficacy, activation, health literacy, resilience, locus of control, personality traits)
Number of subjects: 3083
Study 37427292 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 1725
Study 37427292 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 1725
Study 37427292 — intervention group
Group type: COMPARATOR
Intervention: Vadadustat vs Darbepoetin alfa
Number of subjects: 1725
Study 37427566 — intervention group
Group type: EXPERIMENTAL
Intervention: Single SI (transplant to the duodenum)
Number of subjects: 186
Study 37427566 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated SI (transplant to the duodenum twice)
Number of subjects: 186
Study 37427566 — intervention group
Group type: EXPERIMENTAL
Intervention: All treated groups (single LI, single SI, repeated SI)
Number of subjects: 186
Study 37427566 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186
Study 37427705 — intervention group
Group type: EXPERIMENTAL
Intervention: FX concentrate (Coagadex)
Number of subjects: 2
Study 37427705 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring FX activity post-surgery
Number of subjects: 2
Study 37428030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce cardiovascular risk; details on dosage and duration not available.
Number of subjects: 0
Study 37428030 — intervention group
Group type: COMPARATOR
Intervention: Control group; details not available.
Number of subjects: 0
Study 37428131 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning network (UNet)
Number of subjects: 337
Study 37428131 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning network (YNet)
Number of subjects: 337
Study 37428131 — intervention group
Group type: COMPARATOR
Intervention: Grader comparison
Number of subjects: 337
Study 37428131 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal GA lesion area enlargement correlations from screening to 12 months (n = 53)
Number of subjects: 337
Study 37428131 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal GA lesion area enlargement correlations from screening to 6 months (n = 77)
Number of subjects: 337
Study 37428139 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringers (LR)
Number of subjects: 999
Study 37428139 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (C)
Number of subjects: 999
Study 37428195 — intervention group
Group type: EXPERIMENTAL
Intervention: Examined lymph node (ELN) count
Number of subjects: 7694
Study 37428195 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal ELN count of 15
Number of subjects: 7694
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 methylation in BCC patients
Number of subjects: 50
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 methylation in cSCC patients
Number of subjects: 50
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 methylation in BSC patients
Number of subjects: 50
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA expression in BCC patients
Number of subjects: 50
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA expression in cSCC patients
Number of subjects: 50
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA expression in BSC patients
Number of subjects: 50
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 protein expression in cSCC patients
Number of subjects: 50
Study 37428273 — intervention group
Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA levels in poorly differentiated cSCC patients
Number of subjects: 50
Study 37428347 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus Aromatase Inhibitor (AI)
Number of subjects: 196
Study 37428347 — intervention group
Group type: COMPARATOR
Intervention: Aromatase Inhibitor (AI) monotherapy
Number of subjects: 196
Study 37428348 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 110
Study 37428348 — intervention group
Group type: COMPARATOR
Intervention: Iodopovidone
Number of subjects: 110
Study 37428355 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Health Coaching and Remote Exercise Monitoring for Peripheral Artery Disease (TeGeCoach) program
Number of subjects: 1685
Study 37428355 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1685
Study 37428480 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg; maximum dose, 1000 mg)
Number of subjects: 1971
Study 37428480 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenicriviroc (300-mg loading dose followed by 150 mg twice per day)
Number of subjects: 1971
Study 37428480 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 1971
Study 37428480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1971
Study 37428504 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprescribing intervention (physician-pharmacist collaborative drug therapy management, standard-of-care practice recommendations, shared decision-making, and deprescribing protocols administered by telephone for a maximum of 180 days)
Number of subjects: 2470
Study 37428504 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2470
Study 37428533 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital outpatient service intervention (6-month duration)
Number of subjects: 165
Study 37428533 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 165
Study 37428547 — intervention group
Group type: EXPERIMENTAL
Intervention: AI platform (Eleos Health)
Number of subjects: 47
Study 37428547 — intervention group
Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 47
Study 37428653 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose regimen of Ad5-nCoV vaccine
Number of subjects: 63
Study 37428653 — intervention group
Group type: COMPARATOR
Intervention: One-dose regimen of Ad5-nCoV vaccine
Number of subjects: 63
Study 37428681 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious stimulation during incision stage
Number of subjects: 34
Study 37428681 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxious stimulation during insufflation stage
Number of subjects: 34
Study 37428681 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-opioid administration
Number of subjects: 34
Study 37428866 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental ready-to-use therapeutic food (RUTF) with moderate-dose hydroxyurea therapy (20 mg/kg per day)
Number of subjects: 110
Study 37428866 — intervention group
Group type: COMPARATOR
Intervention: Supplemental ready-to-use therapeutic food (RUTF) without moderate-dose hydroxyurea therapy
Number of subjects: 110
Study 37428883 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered group (informed preoperative education, choice of narcotic quantities)
Number of subjects: 154
Study 37428883 — intervention group
Group type: COMPARATOR
Intervention: Standard group (standard preoperative education, standard narcotic quantities)
Number of subjects: 154
Study 37429122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) titration according to Group A protocol
Number of subjects: 62
Study 37429122 — intervention group
Group type: COMPARATOR
Intervention: Vagus Nerve Stimulation (VNS) titration according to other protocols (Group B and Group C)
Number of subjects: 62
Study 37429122 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS) titration (all groups)
Number of subjects: 62
Study 37429302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously on day 1 of every 21-day cycle for a maximum of 24 months
Number of subjects: 97
Study 37429302 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 97
Study 37429376 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior Transversus Abdominis Plane (TAP) block
Number of subjects: 90
Study 37429376 — intervention group
Group type: COMPARATOR
Intervention: Lateral Quadratus Lumborum Block (QLB)
Number of subjects: 90
Study 37429432 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 70
Study 37429432 — intervention group
Group type: COMPARATOR
Intervention: Intravenous insulin infusion
Number of subjects: 70
Study 37429432 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 70
Study 37429622 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15% ropivacaine injected, 1 mL at a time, up to 1.0 mL.kg
Number of subjects: 40
Study 37429622 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetics of 0.223, 0.591, and 0.797 mL.kg
Number of subjects: 40
Study 37429630 — intervention group
Group type: EXPERIMENTAL
Intervention: ticagrelor-ASA
Number of subjects: 6412
Study 37429630 — intervention group
Group type: COMPARATOR
Intervention: clopidogrel-ASA
Number of subjects: 6412
Study 37429637 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial cardiomyopathy (AC) criteria met (79 NT-proBNP, 47 PTFV1, 4 LADI)
Number of subjects: 183
Study 37429637 — intervention group
Group type: EXPERIMENTAL
Intervention: C reactive protein >3 mg/L
Number of subjects: 183
Study 37429637 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 183
Study 37429637 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial volume index >34 mL/m²
Number of subjects: 183
Study 37429687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (CsA) as first-line treatment for atopic dermatitis.
Number of subjects: 0
Study 37429687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciclosporin (CsA) therapy (for patients already receiving or who have received CsA).
Number of subjects: 0
Study 37429692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping study including a survey of stakeholders (healthcare professionals, people with ADHD and commissioners)
Number of subjects: 30
Study 37429692 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study involving semi-structured interviews with stakeholders (10-15 healthcare professionals and 10-15 people with ADHD)
Number of subjects: 30
Study 37429692 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshops integrating findings from mapping and qualitative studies
Number of subjects: 30
Study 37429923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) + lenvatinib (20 mg daily)
Number of subjects: 0
Study 37429923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) + anti-CTLA-4 quavonlimab (25 mg every 6 weeks)
Number of subjects: 0
Study 37429923 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks) + anti-LAG-3 favezelimab (200 mg or 800 mg every 3 weeks)
Number of subjects: 0
Study 37429947 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery after proximal femoral fracture
Number of subjects: 163
Study 37429972 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game intervention (≥2 hours exposure)
Number of subjects: 35
Study 37429972 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 35
Study 37430077 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zeaxanthin (Zx) 20 mg daily for ≥ 5 years
Number of subjects: 227
Study 37430077 — intervention group
Group type: COMPARATOR
Intervention: CATT historical controls
Number of subjects: 227
Study 37430233 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual dose lipid emulsion
Number of subjects: 0
Study 37430233 — intervention group
Group type: COMPARATOR
Intervention: Reduced dose lipid emulsion (half of the usual dose)
Number of subjects: 0
Study 37430269 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School-based program (8 weeks, 14 practical sessions, 2 theoretical sessions)
Number of subjects: 40
Study 37430269 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual lifestyle)
Number of subjects: 40
Study 37430281 — intervention group
Group type: EXPERIMENTAL
Intervention: Decompression surgery
Number of subjects: 86
Study 37430281 — intervention group
Group type: COMPARATOR
Intervention: Decompression and fusion surgery
Number of subjects: 86
Study 37430291 — intervention group
Group type: EXPERIMENTAL
Intervention: Flap positioned 2 mm below the bone crest (apical group)
Number of subjects: 16
Study 37430291 — intervention group
Group type: COMPARATOR
Intervention: Flap at the level of bone crest (crestal group)
Number of subjects: 16